A Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer.
Ji-Jung Jung, Hee Jeong Kim, Byung Joo Chae...
https://pubmed.ncbi.nlm.nih.gov/41311332/Actively Recruiting
Led by Seoul National University Hospital · Updated on 2026-01-28
464
Participants Needed
1
Research Sites
260 weeks
Total Duration
Researchers are evaluating whether skipping axillary lymph node surgery after neoadjuvant chemotherapy is as safe as performing sentinel lymph node biopsy SLNB in breast cancer patients who show no lymph node involvement on ultrasound. This phase III trial aims to understand if avoiding axillary surgery affects 5-year disease-free survival, building on previous studies that suggest some patients may not need this surgery to reduce complications without compromising outcomes. Participants will be randomly assigned to one of two groups. One group will have breast-conserving surgery BCS without any axillary surgery, while the other group will have BCS with SLNB, possibly including axillary lymph node dissection ALND. The study compares these approaches after patients complete neoadjuvant chemotherapy and shows no lymph node involvement on ultrasound. During the trial, participants will be monitored over five years for invasive disease-free survival, overall survival, distant metastasis-free survival, and rates of axillary and locoregional recurrence. Quality of life will also be assessed for one year. The study involves regular clinical evaluations, imaging, and questionnaires to track outcomes and safety, with the goal of minimizing unnecessary surgical procedures and related complications.
CONDITIONS
No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy
W
Wonshik Han, MD, PhD.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Seoul National University Hospital
Lead Sponsor
Asan Medical Center
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single surgical treatment after completion of chemotherapy
Participants receive breast-conserving surgery (BCS) after neoadjuvant chemotherapy, either without axillary surgery (experimental group) or with sentinel lymph node biopsy (SLNB) with or without axillary lymph node dissection (ALND) (control group).
1 surgical visit
Duration - Up to 5 years
Participants are monitored for up to 5 years to assess disease-free survival, overall survival, recurrence rates, and quality of life.
Regular visits over 5 years (specific schedule not defined)
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ji-Jung Jung, Hee Jeong Kim, Byung Joo Chae...
https://pubmed.ncbi.nlm.nih.gov/41311332/Ji Gwang Jung, Se Hyun Ahn, Seeyoun Lee...
https://pubmed.ncbi.nlm.nih.gov/35184724/Seoul National University Hospital
Lead Sponsor
Asan Medical Center
Collaborating Sponsor